Renaissance Capital logo

Abivax Priced, Nasdaq: ABVX

Late-stage French biotech developing therapies for chronic inflammatory diseases.

Industry: Health Care

Latest Trade: $9.78 0.00 (0.0%)

First Day Return: -28.4%

Return from IPO: -15.7%

Industry: Health Care

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (“UC”). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease (“CD”), as well as evaluating other potential inflammatory indications. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases (“IBD”), chronic conditions involving inflammation of the gastrointestinal (“GI”) tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of approximately 2.9 million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5 million of these patients in the United States alone.
more less
IPO Data
IPO File Date 09/29/2023
Offer Price $11.60
Price Range $11.60 - $13.00
Offer Shares (mm) 20.3
Deal Size ($mm) $236
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/19/2023
Offer Price $11.60
Price Range $11.60 - $13.00
Offer Shares (mm) 20.3
Deal Size ($mm) $236
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Leerink Partners
more
Company Data
Headquarters Paris, France
Founded 2013
Employees at IPO 34
Website www.abivax.com

Abivax (ABVX) Performance